ĐẶC ĐIỂM LÂM SÀNG, CẬN LÂM SÀNG BỆNH NHÂN ĐANG DÙNG THUỐC CHỐNG ĐÔNG MÁU ĐƯỜNG UỐNG VÀO CẤP CỨU VỚI BẤT KÌ CHẢY MÁU NÀO

Abstract

Objective: This study aimed to indentify bleeding complications in patients who were taking oral anticoagulants and compare the characteristics between DOAC and VKAs groups in clinical practice. Subjects and methods: The study describes patients diagnosed with bleeding, in the past medical history taking oral anticoagulants who presented to our emergency department rom April 2022 to August 2023 with any bleeding events. Results: Our study yielded 57 cases of patients taking a VKAs and 29 patiens taking a DOAC (dabigatran, rivaroxaban, apixaban). The rate of gastrointestinal bleeding was higher in patients taking DOACs, and intracranial bleeding was higher in patient taking VKAs (p- 0,89, p= 0,052, respectively). The rate of major bleeding was higher in the VKAs group (p=0,04). The average age of DOAC group was hingher (p<0,01).  Conclusion: There was no significant differences between gastrointestinal bleeding in the warfarin and NOACs groups, but the rate of major bleeding and the rate of intracranial bleeding tended to be higher in VKAs group. Need for close monitoring of the intensity of anticoagulation effect using the international normalized ratio, group DOAC is not required. The use of warfarin by elderly patients is less risky than the use of NOACs in terms of bleeding complications.